Non-Invasive Blood Pressure Monitoring

NCT ID: NCT05825937

Last Updated: 2025-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate an alternative way of continuously measuring blood pressure in patients coming for complex surgery. The investigators will directly compare the speed of set up and accuracy of the new ClearSight monitor to those taken by the arterial line monitor, which is the current gold standard for recording blood pressure measurements.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Continuous invasive arterial line monitoring is the most accurate way to monitor a patient's hemodynamics. Being able to rapidly detect a spike or drop in blood pressure is crucial in the care of both surgical and critically ill patients. Major fluctuations in blood pressure have been associated with bleeding, cardiac damage, cognitive dysfunction, stroke, and acute kidney injury. The impact of poor blood pressure control on patient outcomes is influenced not only by how high or low the pressure gets, but how long it remains at those extremes. The alternative to continuous blood pressure monitoring is to use intermittent non-invasive blood pressure cuffs, which typically display a blood pressure measurement every 5 minutes when being used in the operating room. While this might be sufficient for routine, short surgeries and monitoring in stable patients, blood pressure cuffs are inadequate for patients who are unstable or undergoing extensive surgery.

An arterial line monitor involves the insertion of a catheter into the radial artery and allows for the beat by-beat monitoring of blood pressure. The insertion of this monitor is painful, time consuming, and puts the patient at risk of infection, bleeding, nerve injury, and damage to the artery. There are many factors that can complicate the insertion of the arterial line including the presence of peripheral vascular disease, small arteries, large body habitus, and poor patient cooperation. In view of these problems, researchers have investigated non-invasive monitoring systems as alternatives to invasive arterial cannulation, but these data are limited and inconsistent.

A alternative device called the ClearSight monitor, produced by Edwards LifeSciences, provides continuous noninvasive blood pressure monitoring. The ClearSight monitor connects to the patient by wrapping an inflatable cuff around their finger. It will detect the blood volume fluctuations in the finger that occur with each heartbeat. It then converts that volume change data into beat-by-beat hemodynamic information, including blood pressure, mean arterial pressure, cardiac output, stroke volume and stroke volume variation. The ClearSight monitor was developed to advance hemodynamic monitoring of moderate-to high-risk surgery patients, including elderly and obese patients.

Patients receiving elective cardiac or cerebrovascular disease are an ideal population to study. These patients require continuous blood pressure monitoring to prevent radical swings in blood pressure (either high or low), which can put the patient at risk of intracranial hemorrhage and increased intracranial pressure, or tissue ischemia, respectively. In addition, these patients frequently have many comorbid conditions including coronary artery disease, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, hypertension, liver disease, renal disease, obesity, malignancy, and diabetes. Many of these health conditions may compromise and affect ClearSight system's ability to analyze blood pressure. For example, peripheral vascular disease, diabetes, and hypertension can cause arterial damage, arterial stenosis and reduced blood flow to the hands and feet. Consequently, it will be informative to test the ClearSight's accuracy in this medically challenging patient demographic.

The current standard of care for patients coming for elective cardiac or neurointerventional procedures at Royal University Hospital is an invasive arterial cannulation. The purpose of this study is to compare the systolic blood pressure, diastolic blood pressure, and mean arterial blood pressure measured by the non-invasive blood pressure monitor (ClearSight) versus the invasive radial arterial cannulation in these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elective Cardiac Surgery Patients

Patients having elective cardiac surgery, who have given written consent, will have the ClearSight device, along with the standard radial arterial line.

ClearSight System

Intervention Type DEVICE

Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.

Elective Neurointerventional Surgery Patients

Patients having elective neurointerventional surgery, who have given written consent, will have the ClearSight device, along with the standard radial arterial line.

ClearSight System

Intervention Type DEVICE

Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ClearSight System

Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* written informed consent
* undergoing elective cardiac surgery OR elective neurointerventional surgery (with standard arterial radial line for continuous blood pressure monitoring)

Exclusion Criteria

* undergoing emergent cardiac surgery OR emergent neurointerventional surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Saskatchewan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peter Hedlin

Clinical Scientist, Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Hedlin, PhD MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

University of Saskatchewan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal University Hospital

Saskatoon, Saskatchewan, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peter Hedlin, PhD MD FRCPC

Role: CONTACT

306-655-1183

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Peter Hedlin, PhD MD FRCPC

Role: primary

306-655-1183

References

Explore related publications, articles, or registry entries linked to this study.

Rogge DE, Nicklas JY, Schon G, Grothe O, Haas SA, Reuter DA, Saugel B. Continuous Noninvasive Arterial Pressure Monitoring in Obese Patients During Bariatric Surgery: An Evaluation of the Vascular Unloading Technique (Clearsight system). Anesth Analg. 2019 Mar;128(3):477-483. doi: 10.1213/ANE.0000000000003943.

Reference Type BACKGROUND
PMID: 30649073 (View on PubMed)

Dahan A, Engberts DP, Niesters M. Arterial Line Placement: Safety First. Anesthesiology. 2016 Mar;124(3):528-9. doi: 10.1097/ALN.0000000000000968. No abstract available.

Reference Type BACKGROUND
PMID: 26606174 (View on PubMed)

Goncin U, Liu KK, Rawlyk B, Dalkilic S, Walker MEJ, Norton J, Hedlin P. Comparison of the ClearSight finger cuff monitor versus invasive arterial blood pressure measurement in elective cardiac surgery patients: a prospective observational study. Can J Anaesth. 2024 Nov;71(11):1495-1504. doi: 10.1007/s12630-024-02834-x. Epub 2024 Sep 24.

Reference Type DERIVED
PMID: 39317830 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

USask-1795

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ClearSight System CHN Study
NCT03807622 COMPLETED